Jan 14, 2021 / 02:10PM GMT
Unidentified Analyst -
Good morning, good afternoon and good evening depending on where you are. My name is [Sreenivasan], and I'm a member of the JPMorgan Investment Banking team. It is my pleasure to introduce to you Jack Khattar, CEO of Supernus.
Jack, I'll turn it over to you.
Jack A. Khattar - Supernus Pharmaceuticals, Inc. - Founder, President, CEO, Secretary & Director
Thank you, and thanks for having us today. Good morning, everyone, and thanks for joining us. Before I start, I would like to start on Slide 2, just to remind everyone that I will be making forward-looking statements through the presentation as well as the Q&A session, so please refer to our SEC filings for all the risk factors associated with our business.
Turning to Slide 3. It shows you the execution in CNS and the experience in CNS that Supernus has had over so many years, 20-plus years of CNS expertise. Developing actually 4 products in ADHD, and that is very relevant to us today as we speak a little bit more in details about SPN-812, which is our lead pipeline asset
Supernus Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers